Imugene (ILA) 2025 Extraordinary General Meeting Transcript

Summary of Imugene (ILA) 2025 Extraordinary General Meeting Company Overview - Company: Imugene (ILA) - Industry: Clinical stage cancer therapeutics - Focus: Development of CAR T cell therapies and oncolytic viruses targeting blood cancers Key Points from the Meeting Meeting Structure and Attendance - The meeting was hybrid, allowing both in-person and virtual participation [1][2] - A quorum was established, and the meeting was declared open by the executive chairman, Paul Hopper [1][2] Resolutions and Voting - Resolution 1: Ratification of the prior issue of 68,200,000 placement shares - Votes: 21,900,000 in favor (92.3%), 1,400,000 against, 7.6% abstained [12] - Resolution 2: Approval to issue up to 51,100,000 placement attaching options at an exercise price of 43¢ - Votes: 27,700,000 in favor, 1,600,000 against, 7.6% abstained [14] - Resolution 3: Approval to issue up to 45.4 million new shares at a price of 33¢ per share and up to 34 million attaching options - Votes: 19.5 million in favor, 1.5 million against, 18,000 abstained [17] Financial and Operational Highlights - The company has reduced its workforce from around 100 to the low twenties to cut costs [25][26] - Imugene has out-licensed its manufacturing to a CDMO called Kinsel to offset costs [25] Clinical Development Updates - Focus on allogeneic CAR T cell therapy targeting blood cancers, specifically relapsed diffuse large B cell lymphoma - Reported a 79% overall response rate, with some patients cancer-free for over 16 months [24][25] - Anticipates initiating a pivotal Phase 2/3 registrational study in 2026 after meeting with the FDA [25][28] Upcoming Milestones - Continued data release from Phase 1b studies and submission for various FDA designations to expedite pivotal studies [28][29] - Plans to meet with the FDA in Q4 of the current year to strategize on the pivotal study [28] General Remarks - The company continues to participate in major scientific conferences to showcase data and explore partnering opportunities [26] - No questions were raised from shareholders during the meeting [30][31] Additional Important Information - The results of the voting will be sent to the ASX once available [31] - The meeting concluded with appreciation for shareholder support [31]